Finding 1219154 (2025-001)

Material Weakness Repeat Finding
Requirement
B
Questioned Costs
-
Year
2025
Accepted
2026-06-26
Audit: 405089
Organization: Beth Israel Lahey Health, Inc. (MA)
Auditor: KPMG LLP

AI Summary

  • Core Issue: Inconsistent adherence to salary limitations and inadequate documentation for federal awards led to unallowable costs at BIDMC and Joslin Diabetes Center.
  • Impacted Requirements: Violations of 2 CFR 200 regarding allowable costs, internal controls, and documentation standards for federal awards.
  • Recommended Follow-Up: Enhance internal controls to ensure compliance with salary caps, accurate cost allocation, and proper documentation for all federal expenditures.

Finding Text

BETH ISRAEL LAHEY HEALTH, INC. AND AFFILIATES Schedule of Findings and Questioned Costs Year ended September 30, 2025 Criteria: Title 2 U.S. Code of Federal Regulations Part 200 (2 CFR 200) Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, Section 200.430(a) states that compensation for personal services includes all remuneration, paid currently or accrued, for services of employees rendered during the period of performance under the Federal award, including but not necessarily limited to wages and salaries. Costs of compensation are allowable to the extent the compensation is reasonable for the services rendered and conforms to the established written policy of the recipient or subrecipient consistently applied to both Federal and non-Federal activities; follows an appointment made in accordance with the recipient's or subrecipient's laws, rules, or written policies and meets the requirements of Federal statute, where applicable; and is determined and supported by records that accurately reflect the work performed. 2 CFR 200.403(b) further states costs must meet the criteria of conforming to any limitations or exclusions set forth in these principles or in the Federal award as to types or amount of cost items to be allowable under Federal awards. This includes the auditor to determine if the awards contain any negotiated wage or salary rates, or contain any restrictions on salaries and wages, such as the NIH restriction on the amount that may be charged for individual salaries (https://grants.nih.gov/grants/policy/salcap_summary.htm). Additionally, 2 CFR 200.400(d) requires the accounting practices of the recipient and subrecipient to be consistent with the cost principles and support the accumulation of costs as required by the cost principles, including maintaining adequate documentation to support costs charged to the Federal award. Furthermore, 2 CFR 200.403 states the factors affecting allowability of costs. These factors include the cost to (a) be necessary and reasonable for the performance of the Federal award and be allocable thereto under these principes and (g) be adequately documented to meet the criteria to be allowable under Federal awards. In addition, 2 CFR 200.303 requires nonfederal entities to, among other things, establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Condition: During our testing of payroll for Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Beth Israel Lahey Health, Inc., management did not consistently adhere to the specific award conditions set forth in the Notice of Award (NOA) related to salary limitations for 1 out of 12 of our samples related to our testing. The control operator applied an erroneous National Institutes of Health (NIH) Salary Cap limit when calculating the payroll allocation for an individual’s time allocated to a specific NIH grant selected for testing. As a result, the portion of the individual’s salary charged to the federal grant exceeded the maximum allowable NIH Salary Cap, resulting in an unallowable cost of $41 charged to the award. Furthermore, Joslin Diabetes Center (the Center), an affiliate of Beth Israel Lahey Health, Inc., manually matches purchase orders to the corresponding invoice once received. During our testing for 1 out of 25, we identified an invoice that was incorrectly matched to the purchase order for the Federal award selected for testing. This invoice was processed for payment and subsequently included in the monthly reimbursement draw. At the time of testing, the correct invoice corresponding to the valid purchase order for the selected grant had not yet been received by the Center. This resulted in the expenditure in the amount of $14 being BETH ISRAEL LAHEY HEALTH, INC. AND AFFILIATES Schedule of Findings and Questioned Costs Year ended September 30, 2025 allocated to the incorrect Federal award as well as the Federal award charged not being supported by adequate documentation. Cause: The conditions results from a lack of effective operation of internal controls over the allowability of costs related to Federal awards; specifically, ensuring the cost conforms to any limitations set forth in the Federal award as to the amount of cost items at BIDMC as well as ensuring the cost is allocable to the Federal grant and is adequately documented at the Center. Possible Asserted Effect: Failure to maintain sufficient internal controls to ensure a cost is allowable to a Federal award may result in unallowable costs being charged to Federal awards. Questioned Costs: None. Statistical Sampling: The sample was not intended to be, and was not, a statistically valid sample. Identification of Whether the Audit Finding was a Repeat Finding: This is not a repeat finding. Recommendation: We recommend that BILH enhance its internal controls over Federal award expenditures to ensure, where applicable, all costs charged to Federal awards conform to any limitations or salary caps set forth in the Federal award agreement, are accurately allocated to the correct grant and are adequately documented.

Corrective Action Plan

Management Response and Corrective Action Plan Finding 2025-001 – Allowability Federal Agency: United States Department of Health and Human Services Program Name: Research and Development (R&D) Assistance Listing Number: 93.859 Responsible Individual: BIDMC – Jarod Kohr, Director, Research Finance or The Center - Roy Bourne, Director, Research Finance and Operations Contact Information: BIDMC - jkohr@bidmc.harvard.edu; 617-216-7479 The Center - rbourne2@joslin.harvard.edu; 617-309-5741 A review of Beth Israel Deaconess Medical Center’s (BIDMC) salary allocation process revealed 53 instances out of approximately 11,000 records of allocation in excess of NIH Salary Cap limits (0.04%). BIDMC acknowledges discovery of system limitations that will correct future instances. Accordingly, management has concluded that controls are operating as intended, but will be enhanced to limit human errors. Corrective Action Plan: - Management will implement a calculation control that will prevent the ability to save changes to salary allocation that exceeds the salary cap for the respective period. (Completed) - Management will implement a calculation control that will prevent the ability to reflect a percent salary higher than the percent effort for any salary cap controlled grant. (Completed) - Management will monitor monthly changes to effort/salary allocations in the Time and Effort system for calculated variances. (Ongoing) Expected Completion Date: October 1, 2026 Status of Completion: In process The Center’s management acknowledges that an invoice was incorrectly matched to a purchase order; however, this was not reflective of the overall control environment. The Center maintains established controls over purchase order invoice processing, including system-generated duplicate invoice detection, cost matching tolerances, and restrictions preventing matching to closed purchase orders. Transactions outside established parameters are automatically flagged for manual review. Management performed a targeted review of these transactions, noting expenditures were properly allocated with the exception of the item noted in this finding. Accordingly, management has concluded that controls are operating effectively overall, Accordingly, management has concluded that controls are operating effectively overall, while continuing to evaluate and enhance processes to further mitigate the risk of recurrence. Corrective Action Plan: - Management will reinforce matching requirements through targeted training and communication with Accounts Payable and Purchasing (Completed) - Periodic reconciliation reviews will be performed to identify and correct any misallocated costs as necessary (Completed) - The Center’s planned implementation of a new ERP system on October 1, 2026 will introduce enhanced automated matching controls, further reducing the likelihood of recurrence Expected Completion Date: October 1, 2026 Status of Completion: In process

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 1219153 2025-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.RD8 RESEARCH AND DEVELOPMENT $7.19M
93.493 CONGRESSIONAL DIRECTIVES $2.00M
93.083 PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES $1.98M
93.273 ALCOHOL RESEARCH PROGRAMS $1.81M
93.384 ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) $1.29M
93.696 CERTIFIED COMMUNITY BEHAVIORAL HEALTH CLINIC EXPANSION GRANTS $993,979
81.RD2 RESEARCH AND DEVELOPMENT $702,340
93.310 TRANS-NIH RESEARCH SUPPORT $665,417
93.186 NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE $553,474
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $467,109
12.910 RESEARCH AND TECHNOLOGY DEVELOPMENT $376,144
43.001 SCIENCE $367,581
43.003 EXPLORATION $345,306
93.242 MENTAL HEALTH RESEARCH GRANTS $335,459
11.307 ECONOMIC ADJUSTMENT ASSISTANCE $331,079
93.215 HANSEN'S DISEASE NATIONAL AMBULATORY CARE PROGRAM $313,342
93.RD5 RESEARCH AND DEVELOPMENT $309,188
93.853 EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS $253,429
93.788 OPIOID STR $227,183
93.865 CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH $171,762
93.867 VISION RESEARCH $168,535
93.846 ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH $162,001
21.027 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS $152,299
93.918 GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE $151,437
93.395 CANCER TREATMENT RESEARCH $143,941
93.988 COOPERATIVE AGREEMENTS FOR DIABETES CONTROL PROGRAMS $130,828
47.070 COMPUTER AND INFORMATION SCIENCE AND ENGINEERING $118,438
93.173 RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS $110,988
93.113 ENVIRONMENTAL HEALTH $110,013
93.914 HIV EMERGENCY RELIEF PROJECT GRANTS $105,387
93.394 CANCER DETECTION AND DIAGNOSIS RESEARCH $100,701
93.307 MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH $91,688
93.399 CANCER CONTROL $89,401
93.286 DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH $85,257
93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH $75,924
93.839 BLOOD DISEASES AND RESOURCES RESEARCH $75,425
93.350 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES $60,187
93.213 RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH $59,427
93.397 CANCER CENTERS SUPPORT GRANTS $59,158
93.959 BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE $56,997
93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING $55,360
17.804 LOCAL VETERANS' EMPLOYMENT REPRESENTATIVE PROGRAM $49,647
64.RD3 RESEARCH AND DEVELOPMENT $43,683
93.RD9 RESEARCH AND DEVELOPMENT $43,165
12.300 BASIC AND APPLIED SCIENTIFIC RESEARCH $39,785
93.353 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT $32,889
93.067 GLOBAL AIDS $32,197
93.989 INTERNATIONAL RESEARCH AND RESEARCH TRAINING $31,499
93.172 HUMAN GENOME RESEARCH $31,413
93.866 AGING RESEARCH $27,674
93.926 HEALTHY START INITIATIVE $25,704
93.226 RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES $22,580
93.879 MEDICAL LIBRARY ASSISTANCE $20,523
93.837 CARDIOVASCULAR DISEASES RESEARCH $18,270
12.750 UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS $16,047
93.396 CANCER BIOLOGY RESEARCH $13,582
97.036 DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS) $12,015
93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS $11,971
93.243 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE $7,533
93.398 CANCER RESEARCH MANPOWER $6,603
12.RD1 RESEARCH AND DEVELOPMENT $6,497
47.075 SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES $5,877
47.041 ENGINEERING $5,542
93.103 FOOD AND DRUG ADMINISTRATION RESEARCH $5,422
98.001 USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS $5,306
93.110 SPECIAL PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE $5,000
93.233 NATIONAL CENTER ON SLEEP DISORDERS RESEARCH $4,173
93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH $3,363
93.393 CANCER CAUSE AND PREVENTION RESEARCH $3,229
93.361 NURSING RESEARCH $2,727
47.084 TECHNOLOGY, INNOVATION, AND PARTNERSHIPS $2,064
93.426 THE NATIONAL CARDIOVASCULAR HEALTH PROGRAM $2,000
93.840 TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS $1,871
93.RD4 RESEARCH AND DEVELOPMENT $1,253
93.RD7 RESEARCH AND DEVELOPMENT $1,067
93.RD6 RESEARCH AND DEVELOPMENT $45
93.360 BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT $-204
43.007 SPACE OPERATIONS $-299
16.320 SERVICES FOR TRAFFICKING VICTIMS $-959
93.351 RESEARCH INFRASTRUCTURE PROGRAMS $-1,371
93.838 LUNG DISEASES RESEARCH $-176,444